The shares of Flex Pharma, Inc. (NASDAQ:FLKS) and CorMedix Inc (NYSE:CRMD) were among the active stocks of the last trading sessions. Flex Pharma, Inc. (NASDAQ:FLKS) soared to 6.86% closing at the price of $0.63 whereas the shares of CorMedix Inc (NYSE:CRMD) soared 20.95% with the increase of 0.22 points closing at the price of $1.27. Flex Pharma, Inc. has currently decrease -85.86% in its stock over the period of 6-months while its rival CorMedix Inc added 445.06% in the previous 6-months.
Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.
Returns and Profitability
Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.
The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Flex Pharma, Inc. (NASDAQ:FLKS) is -119.3% while the ROI of CorMedix Inc (NYSE:CRMD) is 0%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, FLKS’s EBITDA Margin is 0.18 whereas CRMD’s is -2.63.
Both the profitability ratios suggest a mixed sentiment for Flex Pharma, Inc. (NASDAQ:FLKS) and CorMedix Inc (NYSE:CRMD).
EPS & Surprise Factor
Flex Pharma, Inc. (NASDAQ:FLKS) reported $-0.5/share EPS for the previous quarter where analysts were predicting an EPS to be $-0.45/share Thus lagging the analyst Estimates with a Surprise Factor of -11.1 Percent. While, CorMedix Inc (NYSE:CRMD) reported EPS of $-0.1/share in the last quarter. The analysts projected EPS of $-0.1/share depicting a Surprise of 0 Percent.
Taking a look at Earnings per Share, CorMedix Inc tends to be beating the analyst estimates more than Flex Pharma, Inc.. so CRMD is more profitable than FLKS.
Technical Analysis of Flex Pharma, Inc. & CorMedix Inc
Moving average convergence divergence (MACD) shows that Flex Pharma, Inc. (NASDAQ:FLKS) is on a PRICE RELATIVITY trend While CorMedix Inc (NYSE:CRMD) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Flex Pharma, Inc. was in BULLISH territory and CorMedix Inc was in BEARISH territory.
FLKS’s current statistics gauge that the stock candle is BEARISH with HIGH volatility. While CRMD’s candle is BULLISH with LOW.
EPS Growth Rate: FLKS’s 0% versus CRMD’s 0%
Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Flex Pharma, Inc. (NASDAQ:FLKS) is predicted at 0% while CorMedix Inc (NYSE:CRMD) stands at 0%. These numbers suggest that CRMD is more suitable investment in terms of EPS growth rate.
Financial Risk and Liquidity Concerns
The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of FLKS stands at 4.5 while CRMD is at 0.5 whereas the debt ratio of the prior is 0 while the debt ratio of the later is 0.
The values of the both ratios suggest that one is more liquid and other investment is more risk free.
While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 3 for FLKS and 2 for CRMD which means FLKS has Hold rating whereas CRMD has Buy rating.
Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for FLKS is $20 which is 96.85% of its current price while CRMD has price target of 3 which is 57.67% of its current price.
Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.
FLKS currently has price to earning P/E ratio of 0 whereas CRMD has 0 while the forward P/E ratio for the prior stands at 0 and for the later it depicts the value of 0.
The price to Book P/B for FLKS is 0.84, Price to Sale is at 9.64 and for CRMD these ratios stand at 0 and 518.99.